Compare Stocks → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALNANASDAQ:IDRANASDAQ:INMBNASDAQ:ONVONASDAQ:PSTI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsINMBINmune Bio$11.75+1.0%$12.14$5.87▼$14.74$211.74M1.9978,741 shs96,381 shsONVOOrganovo$1.03+2.0%$1.02$0.89▼$2.31$10.14M0.9145,579 shs43,794 shsPSTIPluristem Therapeutics$1.24$0.95▼$3.45$32.35M1.91715,259 shs2,128 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%-66.67%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INMBINmune Bio+1.03%-1.43%-2.97%+4.35%+74.07%ONVOOrganovo+1.98%0.00%+5.10%-7.21%-54.42%PSTIPluristem Therapeutics0.00%0.00%0.00%0.00%0.00%“The Stock Market’s Bull Run is Far from Over” -Barrons (Ad)Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AINMBINmune Bio0.8386 of 5 stars3.50.00.00.01.81.70.0ONVOOrganovo0.8918 of 5 stars0.05.00.00.02.50.01.3PSTIPluristem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNAAllena PharmaceuticalsN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AINMBINmune Bio3.00Buy$16.0036.17% UpsideONVOOrganovoN/AN/AN/AN/APSTIPluristem TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/AIDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AINMBINmune Bio$370K572.26N/AN/A$3.35 per share3.51ONVOOrganovo$370K27.95N/AN/A$1.76 per share0.59PSTIPluristem Therapeutics$20K0.00N/AN/A$1.80 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/AIDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/AINMBINmune Bio-$27.30M-$1.52N/A∞N/A-12,246.88%-52.26%-38.08%N/AONVOOrganovo-$17.26M-$2.17N/AN/AN/A-4,061.12%-182.88%-138.52%7/11/2024 (Estimated)PSTIPluristem Therapeutics-$49.87M-$1.47N/AN/AN/AN/A-100.63%-55.46%N/ALatest ONVO, INMB, IDRA, ALNA, and PSTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/8/2024Q3 2024ONVOOrganovo-$0.41-$0.40+$0.01-$0.40$0.08 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/APSTIPluristem TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNAAllena PharmaceuticalsN/A1.581.58IDRAIdera PharmaceuticalsN/A1.561.56INMBINmune Bio0.053.183.18ONVOOrganovoN/A3.673.67PSTIPluristem Therapeutics0.578.228.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNAAllena Pharmaceuticals7.33%IDRAIdera Pharmaceuticals12.18%INMBINmune Bio12.72%ONVOOrganovo8.23%PSTIPluristem Therapeutics16.94%Insider OwnershipCompanyInsider OwnershipALNAAllena Pharmaceuticals3.70%IDRAIdera Pharmaceuticals5.05%INMBINmune Bio36.10%ONVOOrganovo4.00%PSTIPluristem Therapeutics5.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableINMBINmune Bio1018.02 million11.52 millionOptionableONVOOrganovo1510.04 million9.64 millionOptionablePSTIPluristem Therapeutics15332.35 million30.60 millionOptionableONVO, INMB, IDRA, ALNA, and PSTI HeadlinesSourceHeadlineNBRVF Nabriva Therapeutics plcseekingalpha.com - August 18 at 10:08 PMPluri CEO Issues Shareholder Updatefinance.yahoo.com - July 25 at 8:14 AMPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industriesbenzinga.com - July 25 at 2:34 AMPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industriesfinance.yahoo.com - July 25 at 1:25 AMPluristem (PSTI) Phase III Study Misses Goal, Stock Downfinance.yahoo.com - July 14 at 4:41 PMPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgeryfinance.yahoo.com - July 13 at 5:38 PMPluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary Goalmarkets.businessinsider.com - July 13 at 7:28 AMPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgeryfinance.yahoo.com - July 13 at 7:28 AMPluristem: Fiscal Q3 Earnings Snapshotapnews.com - May 10 at 2:20 PMPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnershipfinance.yahoo.com - March 28 at 7:49 AMPluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialseekingalpha.com - March 23 at 6:10 PMPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusionsfinance.yahoo.com - March 23 at 8:52 AMPluristem Therapeutics, Inc. Common Stock (PSTI)nasdaq.com - March 21 at 8:40 AMPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venturefinance.yahoo.com - March 8 at 9:53 AMPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platformfinance.yahoo.com - February 24 at 8:48 AMPluristem: Fiscal Q2 Earnings Snapshottimesunion.com - February 8 at 7:12 PMWhat Are The Analysts’ Predictions For Pluristem Therapeutics Inc. (NASDAQ: PSTI)?stocksregister.com - January 18 at 3:31 PMThinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?marketwatch.com - January 12 at 10:49 PMPluristem Therapeutics Inc. (NASDAQ: PSTI) Is On The Risestocksregister.com - January 11 at 2:09 PMPluristem Therapeutics Inc. (NASDAQ: PSTI) Must Gain 75.17% To Achieve Consensus Price Targetmarketingsentinel.com - January 10 at 6:05 PMIsrael's Tnuva partners with Pluristem to develop cultured cell-based meatmsn.com - January 10 at 1:04 PMBiotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platformfinance.yahoo.com - January 10 at 1:04 PMPluristem Climbs On Collaboration With Tnuva Of Israel For Commercialization Of Alternative Meatnasdaq.com - January 10 at 1:04 PMIs Pluristem Therapeutics (PSTI) Stock a Good Buy?cnafinance.com - January 10 at 1:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAllena PharmaceuticalsNASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Idera PharmaceuticalsNASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Pluristem TherapeuticsNASDAQ:PSTIPluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.